1. Home
  2. PCRX vs TPC Comparison

PCRX vs TPC Comparison

Compare PCRX & TPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PCRX
  • TPC
  • Stock Information
  • Founded
  • PCRX 2006
  • TPC 1894
  • Country
  • PCRX United States
  • TPC United States
  • Employees
  • PCRX N/A
  • TPC N/A
  • Industry
  • PCRX Biotechnology: Pharmaceutical Preparations
  • TPC General Bldg Contractors - Nonresidential Bldgs
  • Sector
  • PCRX Health Care
  • TPC Consumer Discretionary
  • Exchange
  • PCRX Nasdaq
  • TPC Nasdaq
  • Market Cap
  • PCRX 1.2B
  • TPC 1.0B
  • IPO Year
  • PCRX 2011
  • TPC N/A
  • Fundamental
  • Price
  • PCRX $26.25
  • TPC $37.27
  • Analyst Decision
  • PCRX Buy
  • TPC Strong Buy
  • Analyst Count
  • PCRX 9
  • TPC 2
  • Target Price
  • PCRX $29.89
  • TPC $40.50
  • AVG Volume (30 Days)
  • PCRX 891.6K
  • TPC 744.4K
  • Earning Date
  • PCRX 05-08-2025
  • TPC 05-07-2025
  • Dividend Yield
  • PCRX N/A
  • TPC N/A
  • EPS Growth
  • PCRX N/A
  • TPC N/A
  • EPS
  • PCRX N/A
  • TPC N/A
  • Revenue
  • PCRX $702,772,000.00
  • TPC $4,524,568,000.00
  • Revenue This Year
  • PCRX $8.63
  • TPC $19.51
  • Revenue Next Year
  • PCRX $11.66
  • TPC $14.66
  • P/E Ratio
  • PCRX N/A
  • TPC N/A
  • Revenue Growth
  • PCRX 3.08
  • TPC 8.95
  • 52 Week Low
  • PCRX $11.16
  • TPC $14.50
  • 52 Week High
  • PCRX $31.64
  • TPC $37.77
  • Technical
  • Relative Strength Index (RSI)
  • PCRX 49.37
  • TPC 75.25
  • Support Level
  • PCRX $25.33
  • TPC $36.22
  • Resistance Level
  • PCRX $26.44
  • TPC $37.77
  • Average True Range (ATR)
  • PCRX 0.91
  • TPC 1.14
  • MACD
  • PCRX -0.03
  • TPC -0.10
  • Stochastic Oscillator
  • PCRX 61.96
  • TPC 78.84

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

About TPC Tutor Perini Corporation

Tutor Perini Corp offers general contracting, construction management, and design-build services to private and public customers. The company constructs and repairs transportation infrastructure, water-treatment facilities, and a wide range of buildings. Tutor Perini has three operating segments: Civil, Building, and Specialty Contractors. A majority of its revenue is generated from the Civil segment, which specializes in public works construction and the replacement and reconstruction of infrastructure. Its civil contracting services include construction and rehabilitation of highways, bridges, tunnels, mass-transit systems, military and other government facilities, and water management and wastewater treatment facilities. Geographically, it derives key revenue from the United States.

Share on Social Networks: